| CTR20201110 |
一项在溃疡性结肠炎受试者中评价Guselkumab疗效和安全性的IIb/III期、随机、双盲、安慰剂对照、平行组、多中心研究方案 |
诱导研究1：Guselkumab剂量1 |
溃疡性结肠炎 |
Janssen-Cilag International NV/Janssen-Cilag International NV|Cilag AG/Cilag AG|Janssen R&D,a Division of Janssen Pharmaceutica,NV;Fisher Clinical Services;Fisher Clinical Services GmbH;Fisher BioPharma Services (India) Private Limited/Janssen R&D,a Division of Janssen Pharmaceutica,NV;Fisher Clinical Services;Fisher Clinical Services GmbH;Fisher BioPharma Services (India) Private Limited|西安杨森制药有限公司/Xian-Janssen Pharmaceutical Ltd. |
其它 |
2020-06-10 |
进行中 |
